These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9549645)

  • 21. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study.
    Strandness DE; Dalman RL; Panian S; Rendell MS; Comp PC; Zhang P; Forbes WP
    Vasc Endovascular Surg; 2002; 36(2):83-91. PubMed ID: 11951094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial.
    Beebe HG; Dawson DL; Cutler BS; Herd JA; Strandness DE; Bortey EB; Forbes WP
    Arch Intern Med; 1999 Sep; 159(17):2041-50. PubMed ID: 10510990
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of intermittent claudication with pentoxifylline and cilostazol.
    Tjon JA; Riemann LE
    Am J Health Syst Pharm; 2001 Mar; 58(6):485-93; quiz 494-6. PubMed ID: 11286146
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of cilostazol and pentoxifylline for treating intermittent claudication.
    Dawson DL; Cutler BS; Hiatt WR; Hobson RW; Martin JD; Bortey EB; Forbes WP; Strandness DE
    Am J Med; 2000 Nov; 109(7):523-30. PubMed ID: 11063952
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of age and gender on the pharmacokinetics of ebastine after single and repeated dosing in healthy subjects.
    Rohatagi S; Gillen M; Aubeneau M; Jan C; Pandit B; Jensen BK; Rhodes G
    Int J Clin Pharmacol Ther; 2001 Mar; 39(3):126-34. PubMed ID: 11396753
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preparation and evaluation of oral controlled-release cilostazol formulation: pharmacokinetics and antithrombotic efficacy in dogs and healthy male Korean participants.
    Shin KH; Yoon G; Yoon IS; Park JW
    J Pharm Pharmacol; 2014 Jul; 66(7):961-74. PubMed ID: 24697278
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of withdrawal of drugs treating intermittent claudication.
    Dawson DL; DeMaioribus CA; Hagino RT; Light JT; Bradley DV; Britt KE; Charles BE
    Am J Surg; 1999 Aug; 178(2):141-6. PubMed ID: 10487267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of cilostazol for the treatment of Raynaud's phenomenon in systemic sclerosis patients.
    Negrini S; Spanò F; Penza E; Rollando D; Indiveri F; Filaci G; Puppo F
    Clin Exp Med; 2016 Aug; 16(3):407-12. PubMed ID: 26088182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved oral absorption of cilostazol via sulfonate salt formation with mesylate and besylate.
    Seo JH; Park JB; Choi WK; Park S; Sung YJ; Oh E; Bae SK
    Drug Des Devel Ther; 2015; 9():3961-8. PubMed ID: 26251575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical manifestation of atherosclerotic peripheral arterial disease and the role of cilostazol in treatment of intermittent claudication.
    Grouse JR; Allan MC; Elam MB
    J Clin Pharmacol; 2002 Dec; 42(12):1291-8. PubMed ID: 12463722
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of mild liver impairment on the pharmacokinetics of tezosentan, a drug excreted unchanged into bile.
    Dingemanse J; van Giersbergen PL
    Br J Clin Pharmacol; 2004 Mar; 57(3):344-8. PubMed ID: 14998431
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cilostazol prevents foot ulcers in diabetic patients with peripheral vascular disease.
    de Franciscis S; Gallelli L; Battaglia L; Molinari V; Montemurro R; Stillitano DM; Buffone G; Serra R
    Int Wound J; 2015 Jun; 12(3):250-3. PubMed ID: 23672237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication.
    Brass EP; Cooper LT; Morgan RE; Hiatt WR
    J Vasc Surg; 2012 Feb; 55(2):381-389.e1. PubMed ID: 22119244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of single and multiple oral doses of valsartan/amlodipine (80/5 mg) in healthy Chinese subjects.
    Duan J; Chen J; Yin Q; Karan R; Meiser K; Smith HT; Sunkara G
    Int J Clin Pharmacol Ther; 2012 Jan; 50(1):33-43. PubMed ID: 22192643
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects).
    Hiatt WR; Money SR; Brass EP
    J Vasc Surg; 2008 Feb; 47(2):330-336. PubMed ID: 18155871
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication.
    Soga Y; Yokoi H; Kawasaki T; Nakashima H; Tsurugida M; Hikichi Y; Nobuyoshi M
    J Am Coll Cardiol; 2009 Jan; 53(1):48-53. PubMed ID: 19118724
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial.
    Dawson DL; Cutler BS; Meissner MH; Strandness DE
    Circulation; 1998 Aug; 98(7):678-86. PubMed ID: 9715861
    [TBL] [Abstract][Full Text] [Related]  

  • 38. L-Carnitine plus cilostazol versus cilostazol alone for the treatment of claudication in patients with peripheral artery disease: a multicenter, randomized, double-blind, placebo-controlled trial.
    Goldenberg NA; Krantz MJ; Hiatt WR
    Vasc Med; 2012 Jun; 17(3):145-54. PubMed ID: 22615190
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease.
    Money SR; Herd JA; Isaacsohn JL; Davidson M; Cutler B; Heckman J; Forbes WP
    J Vasc Surg; 1998 Feb; 27(2):267-74; discussion 274-5. PubMed ID: 9510281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease.
    O'Donnell ME; Badger SA; Sharif MA; Makar RR; McEneny J; Young IS; Lee B; Soong CV
    Eur J Vasc Endovasc Surg; 2009 Mar; 37(3):326-35. PubMed ID: 19112032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.